Dietary isoflavones act on bone marrow osteoprogenitor cells and stimulate ovary development before influencing bone mass in pre-pubertal piglets

Effects of resveratrol supplementation on bone growth in young rats and microarchitecture and remodeling in ageing rats

Osteoporosis is a highly prevalent skeletal disorder in the elderly that causes serious bone fractures. Peak bone mass achieved at adolescence has been shown to predict bone mass and osteoporosis related risk fracture later in life. Resveratrol, a natural polyphenol compound, may have the potential to promote bone formation and reduce bone resorption. However, it is unclear whether it can aid bone growth and bone mass accumulation during rapid growth and modulate bone metabolism during ageing. Using rat models, the current study investigated the potential effects of resveratrol supplementation during the rapid postnatal growth period and in late adulthood (early ageing) on bone microarchitecture and metabolism. In the growth trial, 4-week-old male hooded Wistar rats on a normal chow diet were given resveratrol (2.5 mg/kg/day) or vehicle control for 5 weeks. In the ageing trial, 6-month-old male hooded Wistar rats were treated with resveratrol (20 mg/kg/day) or vehicle for 3 months. Treatment effects in the tibia were examined by μ-computer tomography (μ-CT) analysis, bone histomorphometric measurements and reverse transcription-polymerase chain reaction (RT-PCR) gene expression analysis. Resveratrol treatment did not affect trabecular bone volume and bone remodeling indices in the youth animal model. Resveratrol supplementation in the early ageing rats tended to decrease trabecular bone volume, Sirt1 gene expression and increased expression of adipogenesis-related genes in bone, all of which were statistically insignificant. However, it decreased osteocalcin expression (p = 0.03). Furthermore, serum levels of bone resorption marker C-terminal telopeptides type I collagen (CTX-1) were significantly elevated in the resveratrol supplementation group (p = 0.02) with no changes observed in serum levels of bone formation marker alkaline phosphatase (ALP). These results in rat models suggest that resveratrol supplementation does not significantly affect bone volume during the rapid growth phase but may potentially have negative effects on male skeleton during early ageing.

Genistein as a Potential Anticancer Agent against Ovarian Cancer

Genistein is known as the major component of isoflavone, which is present in high-soy diets. Genistein has received much attention because of its chemopreventive and therapeutic effects on various types of cancers. Numerous studies have shown that genistein has antineoplastic effects against ovarian cancer. Several epidemiological studies have shown that women who have high consumption of isoflavones have a relatively low incidence of ovarian cancer. Genistein inhibits ovarian carcinogenesis by pleiotropic mechanisms. A higher affinity to estrogen receptor β is one probable explanation for its ability to reduce the risk of ovarian cancer. Genistein also targets multiple cellular signal transduction pathways associated with cell cycle regulation and apoptosis. In addition, genistein has been suggested to have antiangiogenic and antioxidant activities. Herein, we summarize recent results from epidemiological and experimental studies to identify the role of genistein in ovarian cancer. Further studies are needed to achieve conclusive results and determine the clinical applications of genistein.

Adequate but not supplemental folic acid combined with soy isoflavones during early life improves bone health at adulthood in male mice

Previous investigations from our laboratory have demonstrated that neonatal exposure to soy isoflavones (ISO) improves bone outcomes in CD-1 mice at adulthood with greater benefits in females than males. This study determined whether early-life exposure to supplemental folic acid (FA) - that may enhance DNA methylation of target genes - in combination with ISO provides greater benefits to male bone development than ISO alone. CD-1 dams were randomized to a low (0 mg/kg diet), adequate (2 mg/kg diet) or supplemental (8 mg/kg diet) level of FA during pregnancy and lactation. Offspring received corn oil or ISO (7 mg/kg of body weight per day) from postnatal day 1-10. From weaning, males were fed adequate FA and studied to age 4 months. Offspring exposed to adequate FA+ISO had multiple benefits to bone health: higher (P<.05) bone mineral density (BMD) and greater (P<.05) resistance to fracture at the femur and lumbar spine than mice exposed to adequate FA alone. Exposure to supplemental FA+ISO resulted in higher (P<.05) serum osteoprotegerin (OPG), and a higher ratio of OPG to receptor activator for nuclear factor κβ ligand (RANKL) but did not result in greater BMD or strength at the femur or lumbar spine than supplemental FA alone. In conclusion, early-life exposure to adequate FA+ISO provided functional benefits to male bone development, while improvements induced by supplemental FA+ISO were limited to a higher level of serum OPG. Mechanistic studies are needed to better understand how FA and ISO improve bone development in male offspring.

Standardized ileal digestibilities of crude protein, amino acids, and contents of antinutritional factors, mycotoxins, and isoflavones of European soybean meal imports fed to piglets

A study with 3 experiments and 3 periods each was conducted to assess the protein value of soybean meal (SBM) batches that were imported into the European Union (EU) from Argentina, Brazil, or the United States (US). Six random SBM batches from each origin were analyzed for contents of CP, AA, ether extract, crude ash, NDF, ADF, oligosaccharides, isoflavones, mycotoxins, trypsin inhibitor activity (TIA), and protein dispersibility index. Piglets were used for determination of standardized ileal digestibilities (SID) of CP and AA in these 18 SBM batches. In each experiment, 12 piglets (initial BW = 5.6 ± 0.7 kg) were surgically fitted with simple T-cannulas at the distal ileum. The piglets were randomly allotted to 18 semisynthetic assay diets, which included 1 of the 18 SBM batches from the 3 origins at an inclusion level of 250 g/kg (as-fed). Average content of CP was 480, 505, and 488 g/kg (as-fed) for Argentinean, Brazilian, and US SBM batches, respectively, and was greater for Brazilian SBM (P ≤ 0.05) compared with the other 2 origins. Contents of most AA were greater (P ≤ 0.05) in Brazilian compared with Argentinean SBM batches. Amino acid contents in US SBM batches ranged between those from Argentina and Brazil. Average TIA were 3.9, 5.1, and 3.4 mg trypsin inhibitor/g CP for Argentinean, Brazilian, and US SBM batches, and were greater (P ≤ 0.05) for Brazilian SBM compared with the other origins. Mycotoxins were detected in 8 out of 18 SBM batches, but all mycotoxin concentrations were less than their critical benchmarks. The contents of individual isoflavones varied considerably and differed (P ≤ 0.05) among SBM origins. The SID of CP, Arg, Phe, Thr, Trp, Asp, Gly, and Ser were greater (P ≤ 0.05) for US compared with Argentinean SBM batches, with intermediate values for Brazilian SBM batches. The obtained SID values were most variable within Argentinean SBM batches and most homogenous within US SBM batches, as indicated by great and small CV, respectively. However, SID of CP and AA were not affected (P > 0.05) by any of the chemical variables measured in this study, according to linear and quadratic regression analyses. Greatest SID values and good homogeneity between individual batches of the same origin were observed for US SBM. The results of this study with piglets will expand the database on SID of CP and AA in SBM from 3 of the major soybean-producing and processing countries.

Risks and benefits of dietary isoflavones for cancer

A high intake of fruits and vegetables is associated with a lower risk of cancer. In this context, considerable attention is paid to Asian populations who consume high amounts of soy and soy-derived isoflavones, and have a lower risk for several cancer types such as breast and prostate cancers than populations in Western countries. Hence, interest focuses on soyfoods, soy products, and soy ingredients such as isoflavones with regard to their possible beneficial effects that were observed in numerous experiments and studies. The outcomes of the studies are not always conclusive, are often contradictory depending on the experimental conditions, and are, therefore, difficult to interpret. Isoflavone research revealed not only beneficial but also adverse effects, for instance, on the reproductive system. This is also the case with tumor-promoting effects on, for example, breast tissue. Isoflavone extracts and supplements are often used for the treatment of menopausal symptoms and for the prevention of age-associated conditions such as cardiovascular diseases and osteoporosis in postmenopausal women. In relation to this, questions about the effectiveness and safety of isoflavones have to be clarified. Moreover, there are concerns about the maternal consumption of isoflavones due to the development of leukemia in infants. In contrast, men may benefit from the intake of isoflavones with regard to reducing the risk of prostate cancer. Therefore, this review examines the risks but also the benefits of isoflavones with regard to various kinds of cancer, which can be derived from animal and human studies as well as from in vitro experiments.